News
-
-
-
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma to Present New Clinical Data on Lead ATAC Candidate Pamlectabart Tismanitin at International Myeloma Society Annual Meeting 2026
Heidelberg Pharma to present new clinical data on lead ATAC candidate Pamlectabart Tismanitin at International Myeloma Society Annual Meeting 2026 -
-
-
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma and Huadong Medicine Sign Additional Collaboration Agreement to Jointly Develop New Antibody Drug Conjugates
Heidelberg Pharma and Huadong Medicine sign new collaboration agreement to jointly develop Antibody Drug Conjugates, expanding pipeline with innovative products -
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Heidelberg Pharma and Huadong Medicine Sign Additional Collaboration Agreement to Jointly Develop New Antibody Drug Conjugates
Heidelberg Pharma and Huadong Medicine sign a new collaboration agreement to jointly develop new Antibody Drug Conjugates, broadening their existing partnership and combining proprietary technologies -